Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_361c6223f33de77431dc880348294a7c |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-207 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-16 |
filingDate |
2020-05-08^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2021-03-25^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_434d98a1ceff3eab095884b141893a7e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_575ae645b209afd6ef29f8d5166d1981 |
publicationDate |
2021-03-25^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2020203055-B2 |
titleOfInvention |
Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
abstract |
A compound of the structure: nRl-,N',R2 nN nN n<JN nN22 N R nR40 n0 R12 nOR3 F nor a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected nwith or exposed to an HCV virus or other disorders more fully described herein. |
priorityDate |
2015-03-06^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |